Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Molecular Imaging to Guide Repair and Advance Therapy: Targeting the inflammation-fibrosis axis in ischemic heart disease and remote organs

Project description

Heart repair with molecular imaging

After a heart attack, the heart undergoes a complex repair process involving inflammation and fibroblast activation, which can either help or hinder recovery. However, current treatments have not been able to target these processes effectively. The ERC-funded MIGRATe project is tackling this challenge by using non-invasive molecular imaging to monitor these cellular responses in the heart and connected organs. By combining cutting-edge imaging with molecular biology, MIGRATe will identify key biomarkers and refine therapy timing, promoting better recovery and preventing heart failure. The project will also explore how cardiac therapies impact distant organs, offering a comprehensive approach to healing that could transform treatment strategies for heart attack patients.

Objective

Myocardial infarction triggers a complex interplay between inflammation and fibroblast activation, which contributes to success or failure of adequate repair. Targeted therapeutic approaches to modulate these processes have not yet been implemented clinically. The dynamic and multicellular nature of the inflammatory and fibrotic repair process in the heart is thought to be variable among individuals. Additionally, cardiac injury and treatment affect distant organs through systems-based interaction.
In MIGRATe, I will explore non-invasive molecular imaging approaches to interrogate inflammatory cell populations and fibroblast activation in the heart and networking organs, for precise guidance of targeted therapeutic interventions. Imaging will delineate optimal timing and/or targeting of treatment to support endogenous healing and prevent heart failure progression. MIGRATe will also bring together imaging methods and molecular biology to decode the tissue microenvironment and identify novel biomarkers amenable to imaging and treatment. A combination of in vivo molecular imaging, single cell sorting, and transcriptome data from regions with elevated and/or suppressed imaging signal will be exploited to identify disproportionate cell subpopulations that contribute to the prognostic signal and may be targeted by therapy. Whole body imaging will simultaneously reveal the impact of cardiac cell directed therapy on the heart, alongside distant organ function, providing new insights into inter-organ communication and supporting a wholistic approach towards repair. Experimental work in mouse models will be complemented by a proof-of-concept clinical study, establishing a translational environment. Taken together, MIGRATe is designed to optimize new imaging-guided, molecular-targeted treatment strategies to improve cardiac outcome after acute myocardial infarction with corresponding benefit for reciprocal organ systems.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-COG

See all projects funded under this call

Host institution

HANNOVER CLINICAL TRIAL CENTER GMBH
Net EU contribution
€ 1 933 148,00
Address
CARL NEUBERG STR 1 K 27 OE 9751
30625 Hannover
Germany
Region
Niedersachsen Hannover Region Hannover
Activity type
Research Organisations
Links
Total cost
€ 1 933 148,00

Beneficiaries (1)